Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy extension study of ligelizumab in food allergy
jRCT2031240199Completed
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of ligelizumab in food allergy (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of ligelizumab. Started Aug 2023; status: completed.
02
Drugs
ligelizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on jRCT2031240199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240199.